Shao Tiemei, Zhang Jing, An Shengjun, Xu Hongjun, Wu Jiangli, Wang Lei, Zhao Wei, Zhou Yongjie, Zhou Luyang, Cui Qingzhuo
Hebei Engineering Center of Plant Bioreactor Preparation Technology, Hebei University of Chinese Medicine, Shijiazhuang, China.
Research Center, Hebei University of Chinese Medicine, Shijiazhuang, China.
Cardiovasc Hematol Agents Med Chem. 2022;20(1):34-42. doi: 10.2174/1871525719666210216103421.
Salvia miltiorrhiza (SM) is a traditional Chinese medicine used clinically to treat cardiovascular diseases, including atherosclerosis and myocardial infarction. Its therapeutic effect has been confirmed by many clinical and pharmacological studies. However, the optimal formulation of active ingredients in SM for treating cardiovascular diseases remains unclear. In this study, we determined the ratio of the optimal compatibility of SM ingredients DSS, Sal-A, Sal-B, and PAL (SABP)with a uniform and orthogonal optimized experimental design. In addition, we determined the anti-oxidation effect of SABP using Adventitial Fibroblasts (AFs).
By using a combination of uniform and orthogonal designs, we determined the optimal formulation of aqueous extract from SM. MTT assay was used to determine the inhibitory effects of these 4 components of SM on the AFs, which were isolated and cultured from the aorta. The reactive oxygen species (ROS) production in AFs was compared before and after SABP treatment.
The optimal formulation of these 4 aqueous extracts from SM were 150 : 7 : 300 : 500, and their concentrations were S(1.5×10-4 mol/L), A(7×10-6 mol/L), B(3×10-4 mol/L), and P(5×10-4 mol/L). There were some synergies between these 4 components. Moreover, SABP decreased ROS production in AFs.
These findings suggest that SABP inhibits the proliferation and oxidation stress in AFs. The present study provides new evidence that the efficacy and function generated from the optimal formulation of active ingredients in SM are better than lyophilized powder of SM.
丹参是一种临床上用于治疗心血管疾病(包括动脉粥样硬化和心肌梗死)的传统中药。其治疗效果已得到许多临床和药理学研究的证实。然而,丹参中用于治疗心血管疾病的活性成分的最佳配方仍不清楚。在本研究中,我们采用均匀和正交优化实验设计确定了丹参成分丹酚酸D、丹酚酸A、丹酚酸B和原儿茶醛(SABP)的最佳配伍比例。此外,我们使用外膜成纤维细胞(AFs)测定了SABP的抗氧化作用。
通过结合均匀设计和正交设计,我们确定了丹参水提取物的最佳配方。采用MTT法测定丹参这4种成分对从主动脉分离培养的AFs的抑制作用。比较SABP处理前后AFs中活性氧(ROS)的产生情况。
丹参这4种水提取物的最佳配方为150:7:300:500,其浓度分别为S(1.5×10-4mol/L)、A(7×10-6mol/L)、B(3×10-4mol/L)和P(5×10-4mol/L)。这4种成分之间存在一些协同作用。此外,SABP降低了AFs中ROS的产生。
这些发现表明SABP抑制AFs的增殖和氧化应激。本研究提供了新的证据,表明丹参活性成分最佳配方产生的功效和作用优于丹参冻干粉。